Adial Pharmaceuticals, Inc. ADIL 深 沪
等待开盘 08-27 09:30:00 美东时间
5.94
+0.120
+2.06%
华盛通- 最 高6.07
- 今 开5.84
- 成交量 6.46万股
- 最 低 5.5905
- 昨 收 5.82
- 总市值 1559.78万
- 52周最高 10.75
- 市盈率 静 --
- 换手率 2.46%
- 52周最低 1.31
- 委 比 88.73%
- 总股本 262.59万
- 历史最高 5900.00
- 量 比 0.87
- 振 幅 8.24%
- 历史最低 3.3075
- 每 手 1
- 风险率 2.89%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Altimmune Says Lead Drug Shows Significant Alcohol Reduction in Mid-Stage Study
Altimmune Inc. (NASDAQ:ALT) has reported positive topline outcomes from its RECLAIM Phase 2 trial assessing pemvidutide in patients diagnosed with moderate to severe alcohol use disorder (AUD). The late clinical-stage biopharmaceutical company confirmed that the study successfully met its primary en...
07-28 23:08
美股大行评级 | 大摩再上调希捷科技和西部数据目标价；多家大行首予Lincoln买入评级
今日重点评级关注：HC Wainwright & Co.：维持Elicio Therapeutics"买入"评级，目标价从17美元升至23美元；Leerink Partners：维持SAB Biotherapeutics"跑赢大市"评级，目标价从7美元升至12美元
06-16 11:34
LUCID CAPITAL MARKETS Initiates Coverage On Adial Pharmaceuticals with Buy Rating, Announces Price Target of $6
LUCID CAPITAL MARKETS analyst Elemer Piros initiates coverage on Adial Pharmaceuticals (NASDAQ:ADIL) with a Buy rating and announces Price Target of $6.
06-16 01:18
Adial Pharmaceuticals Q1 EPS $(1.48) Beats $(2.73) Estimate
Adial Pharmaceuticals (NASDAQ:ADIL) reported quarterly losses of $(1.48) per share which beat the analyst consensus estimate of $(2.73) by 45.79 percent. This is a 82.59 percent increase over losses of $(8.50) per share
05-09 06:15
EXCLUSIVE: Adial Pharmaceuticals Clears Manufacturing Milestone Ahead Of Pivotal Study For Alcohol Use Disorder Drug
Adial Pharmaceuticals completes AD04 demo batch, validating process transfer and enabling Phase 3 production and FDA IND updates.
04-22 21:21
Adial Pharmaceuticals Lead Drug Fits New Policy Mood As Bipartisan Bill Signals Broader Lens On Alcohol Use Disorder
Adial backs H.R. 7091 targeting AUD in veterans, spotlighting harm reduction therapies and expanding research beyond abstinence-based care.
03-24 21:13
Adial Pharmaceuticals Q4 EPS $(11.48) Misses $(0.09) Estimate
Adial Pharmaceuticals (NASDAQ:ADIL) reported quarterly losses of $(11.48) per share which missed the analyst consensus estimate of $(0.09) by 12655.56 percent. This is a 206.13 percent decrease over losses of $(3.75) per
03-06 21:07
EXCLUSIVE: Adial Pharma Eyes Europe Deal For Lead Drug For Alcohol Use Disrder Worth Up To $60 Million
Adial Pharma signs Europe deal with Molteni for AD04, eyeing up to $60 million in milestones and royalties.
03-03 21:02
Why Super Micro Computer Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket
Shares of Super Micro Computer Inc (NASDAQ:SMCI) rose sharply in pre-market tra...
02-04 17:33
